Development & Alumni Relations Office 


31 January 2017

Queen’s University is to team up with Cirdan Imaging, a medical imaging company specialising in developing medical devices and software used in surgery and cancer diagnosis, on a multi-million pound R&D project.

Cirdan has been offered £1.4m from Invest NI to support the creation of 46 new jobs over the next four years to help deliver the major R&D in initiative.

Professor Manuel Salto-Tellez and Professor David Gonzalez de Castro, from the Centre for Cancer Research and Cell Biology at Queen’s University Belfast, will lead the collaboration with Cirdan Imaging. He said: “We are delighted to be working in collaboration with Cirdan Imaging on this significant precision medicine R&D project. Healthcare providers will have the relevant equipment to create a personalized treatment plan for patients, resulting in an overall better healthcare system in the future.”

Professor Gonzalez de Castro, added: “The current pace of innovation in precision medicine as a result of novel biological and clinical studies demands an urgent development on integrated workflows and healthcare laboratory solutions. This collaborative project is a significant step forward in the commitment to deliver those solutions.”

Making the announcement during a visit to the company’s premises, Invest NI CEO, Alastair Hamilton, said: “Studies show a solid link between investment in R&D, profitability and growth.

“This R&D project will enable Cirdan to develop new precision medicine product solutions to meet the future need of both existing and new customers.”

CEO of Cirdan Imaging Hugh Cormican, who is a triple Queen’s graduate – Honorary Degree (2003), PhD (1990) and BSc 1984 – said: “Hospital laboratories are undergoing a major transformation as they adopt the new workflows and instrumentation required for the emerging precision medicine model of HealthCare. Working with Queen’s, we intend to be at the forefront of this change, supporting laboratories globally to meet this demand.

“The new jobs will help us identify new markets and new customers, and our R&D investment will mean we can develop new products and expand our exports especially into the markets of Oceania and North America. The support of Invest NI has been invaluable to allow us to make the necessary scale of investment within the required timescales to allow us to compete effectively in these markets.”

Work on the R&D project with Queen’s University will commence in early 2017.

Media inquiries to Communications Office, tel: 028 90 97 3091.

Caption (L-R): Dr James Gerald Doherty, Cirdan Chairman, Samana Hussain-Brannigan, Technology Executive, Invest NI, Dr Hugh Cormican, Alastair Hamilton, Dr Frances Weldon, Business Alliance Manager for Medicine, Health and Life Sciences at Queen’s and Stephen Dunniece, Cirdan R&D Director.

Back to Main News









Top of Page